Abstract
The serine/threonine protein kinase, TBK1, plays a crucial role as the hub for many innate immune signaling pathways that lead to the induction of type I interferon (IFN) and interferon-stimulated genes (ISGs). Due to its key function in maintaining homeostasis of the immune system, cell survival and proliferation, TBK1 activity is tightly regulated. Dysregulation of TBK1 activity is often associated with autoimmune diseases and cancer, implicating the potential therapeutic benefit for targeting TBK1. Tremendous effort from both academic institutions and private sectors during the past few years has led to the development of many potent and selective TBK1 inhibitors, many of which have shown great promise in disease models in vivo. This review summarizes recent advance on the pharmacological inhibition of TBK1 and its potential for treating autoimmune diseases and interferonopathies.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 336-342 |
| Number of pages | 7 |
| Journal | Pharmacological Research |
| Volume | 111 |
| DOIs | |
| State | Published - Sep 1 2016 |
Fingerprint
Keywords
- Autoimmune disease
- Interferonopathy
- Lupus
- TBK1
- Type I interferon
ASJC Scopus subject areas
- Pharmacology
Cite this
Therapeutic potential of targeting TBK1 in autoimmune diseases and interferonopathies. / Hasan, Maroof; Yan, Nan.
In: Pharmacological Research, Vol. 111, 01.09.2016, p. 336-342.Research output: Contribution to journal › Review article
}
TY - JOUR
T1 - Therapeutic potential of targeting TBK1 in autoimmune diseases and interferonopathies
AU - Hasan, Maroof
AU - Yan, Nan
PY - 2016/9/1
Y1 - 2016/9/1
N2 - The serine/threonine protein kinase, TBK1, plays a crucial role as the hub for many innate immune signaling pathways that lead to the induction of type I interferon (IFN) and interferon-stimulated genes (ISGs). Due to its key function in maintaining homeostasis of the immune system, cell survival and proliferation, TBK1 activity is tightly regulated. Dysregulation of TBK1 activity is often associated with autoimmune diseases and cancer, implicating the potential therapeutic benefit for targeting TBK1. Tremendous effort from both academic institutions and private sectors during the past few years has led to the development of many potent and selective TBK1 inhibitors, many of which have shown great promise in disease models in vivo. This review summarizes recent advance on the pharmacological inhibition of TBK1 and its potential for treating autoimmune diseases and interferonopathies.
AB - The serine/threonine protein kinase, TBK1, plays a crucial role as the hub for many innate immune signaling pathways that lead to the induction of type I interferon (IFN) and interferon-stimulated genes (ISGs). Due to its key function in maintaining homeostasis of the immune system, cell survival and proliferation, TBK1 activity is tightly regulated. Dysregulation of TBK1 activity is often associated with autoimmune diseases and cancer, implicating the potential therapeutic benefit for targeting TBK1. Tremendous effort from both academic institutions and private sectors during the past few years has led to the development of many potent and selective TBK1 inhibitors, many of which have shown great promise in disease models in vivo. This review summarizes recent advance on the pharmacological inhibition of TBK1 and its potential for treating autoimmune diseases and interferonopathies.
KW - Autoimmune disease
KW - Interferonopathy
KW - Lupus
KW - TBK1
KW - Type I interferon
UR - http://www.scopus.com/inward/record.url?scp=84979084979&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84979084979&partnerID=8YFLogxK
U2 - 10.1016/j.phrs.2016.04.008
DO - 10.1016/j.phrs.2016.04.008
M3 - Review article
C2 - 27353409
AN - SCOPUS:84979084979
VL - 111
SP - 336
EP - 342
JO - Pharmacological Research
JF - Pharmacological Research
SN - 1043-6618
ER -